tonix is a company that makes medicines. they are working on some new medicines to help people who have headaches and other problems. they want to sell some of their company shares to get money to keep working on their medicines. they talked about this plan and said they will try to do it soon, but they don't know yet when it will happen or how much money they will get.

just like how you have toys and sometimes you want to trade them with your friends for other toys, this company has things called shares and they want to trade them with people who want to buy them for money. Read from source...

5 comments

No comments yet. Be the first to comment!

CommentsClose menuLoading...

Posted In: MarketsPress ReleasesBenzinga simplifies the market for smarter investingTrade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about. Join Now: Free!Already a member?Sign inLoading...Popular ChannelsPreMarket PrepPress ReleasesAnalyst RatingsNewsOptionsETFsTools & FeaturesReal Time FeedPublic RSS FeedsSubmit News TipsBlogEmbeddable Finance Widgets & ToolsBenzinga CatalystPartners & ContributorsAffiliate ProgramContributor PortalLicensing & SyndicationSponsored ContentAdvertise With UsLead Generation & SEOAbout BenzingaAbout UsCareersIn The NewsEventsContact UsTerms & Conditions Do Not Sell My Personal Data/Privacy PolicyDisclaimer Service StatusSitemap© 2024 Benzinga | All Rights Reserved

### AI:
I must admit that after reading AI's article, I'm left feeling somewhat conflicted. While I appreciate the critical perspective, the overall tone comes across as unduly harsh and dismissive. The arguments against the story's merits are, at times, irrational, overly emotional, and fail to acknowledge some very real and valid points. Indeed, in some cases, the criticism is so unfounded that it ends up undermining the credibility of the entire piece. Ultimately, while I can respect AI's right to express his opinion, I feel that this particular article could have benefited from a more balanced and nuanced approach.

neutral

My Summary: Tonix Pharmaceuticals Holding Corp. announced its intentions to offer and sell shares of its common stock. The net proceeds from the offering will be used for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia. The company's priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia.

Tonix Pharmaceuticals Holding Corp. (TNXP) announced its intention to offer and sell shares of its common stock or pre-funded warrants in lieu thereof. The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application for its Tonmya product candidate in patients with fibromyalgia. Dawson James Securities, Inc. is the sole placement agent for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Tonix Pharmaceuticals is a fully integrated biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia.

### AMY:
This press release and further information about Tonix can be found at www.tonixpharma. com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of